To synthesize cardiovascular outcome trials, mechanistic studies, and guideline recommendations regarding incretin-based therapies and their cardiovascular benefits beyond diabetes.
Approach:
Review Methodology: A critical narrative review with structured evidence mapping was conducted, analyzing data from various sources including PubMed/MEDLINE, Embase, and regulatory materials up to April 30, 2026.
Key Findings:
GLP-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Semaglutide 2.4 mg has shown cardiovascular benefits in individuals with obesity and established cardiovascular disease, independent of diabetes.
Emerging dual and triple incretin-based agonists and combination therapies are reshaping treatment algorithms.
The magnitude of cardiovascular benefit varies by molecule, dose, population, and endpoint hierarchy.
Current evidence for newer multi-agonists and oral non-peptide GLP-1 RAs is incomplete.
Interpretation:
Incretin-based cardiovascular protection is biologically plausible and requires careful consideration of trial data and regulatory indications for treatment selection.
Limitations:
Variability in cardiovascular outcome trials regarding background therapy, event rates, and statistical hierarchy limits generalizability.
Semaglutide data cannot be generalized to all GLP-1 RAs.
Weight loss efficacy should not substitute for adjudicated cardiovascular outcomes.
New agents require dedicated cardiovascular outcome data before being positioned as risk-reduction therapies.
Conclusion:
The review highlights the need for a balanced evidence framework to guide the use of incretin-based therapies in cardiovascular practice.
